Vaxart (NASDAQ:VXRT) Stock Price Crosses Below Two Hundred Day Moving Average - What's Next?

Key Points

• Vaxart shares have fallen below their 200-day moving average of $0.42, currently trading at $0.39 with a trading volume of 802,784 shares.
• Institutional investors have shown significant interest, with Marshall Wace LLP and Jones Financial Companies among those increasing their stakes in Vaxart.
• The company is focused on developing oral recombinant protein vaccines, with several products in various stages of clinical trials, including norovirus and coronavirus vaccines.

Shares of Vaxart, Inc. (NASDAQ:VXRT - Get Free Report) crossed below its two hundred day moving average during trading on Friday . The stock has a two hundred day moving average of $0.42 and traded as low as $0.37. Vaxart shares last traded at $0.39, with a volume of 802,784 shares.

Vaxart Trading Up 0.5%

The firm has a market cap of $88.62 million, a PE ratio of -1.43 and a beta of 1.33. The business has a fifty day moving average of $0.38 and a 200-day moving average of $0.42.

Institutional Trading of Vaxart

Several hedge funds and other institutional investors have recently bought and sold shares of VXRT. Marshall Wace LLP acquired a new stake in shares of Vaxart during the 2nd quarter valued at approximately $794,000. Jones Financial Companies Lllp lifted its position in shares of Vaxart by 276,364.7% in the 1st quarter. Jones Financial Companies Lllp now owns 478,284 shares of the biotechnology company's stock valued at $196,000 after acquiring an additional 478,111 shares in the last quarter. Squarepoint Ops LLC grew its stake in Vaxart by 95.0% in the 4th quarter. Squarepoint Ops LLC now owns 516,798 shares of the biotechnology company's stock valued at $342,000 after buying an additional 251,789 shares during the last quarter. Virtu Financial LLC bought a new position in shares of Vaxart during the 1st quarter worth about $56,000. Finally, Goldman Sachs Group Inc. acquired a new stake in Vaxart in the 1st quarter valued at about $31,000. Institutional investors own 18.05% of the company's stock.

Vaxart Company Profile

Vaxart, Inc, a clinical-stage biotechnology company, discovers and develops oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company's product pipeline includes norovirus vaccine, a bivalent oral tablet vaccine in Phase 2 clinical trial for the GI.1 and GII.4 norovirus strains; coronavirus vaccine, which is in Phase 2 clinical trial, for the treatment of SARS-CoV-2 infection; seasonal influenza vaccine, which is in Phase 2 clinical trial, to treat H1 influenza infection; and human papillomavirus therapeutic vaccine, which is in preclinical stage, that targets HPV-16 and HPV-18 for cervical cancers and precancerous cervical lesions.